EMEA says clarification on dedicated facilities forthcoming
This article was originally published in The Gold Sheet
Executive Summary
EMEA said a clarification on the status of the revision of Chapter 5 of its EU GMP guide concerning dedicated facilities will be available at the end of the year. Section 6 of Chapter 5 GMP Guide currently states that "in order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular medicinal products such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. from live microorganisms)." It further noted that "the production of certain additional products such as certain antibiotics certain hormones, certain cytotoxics, certain highly active drugs and non-medicinal products should not be conducted in the same facilities. However, the guidance does not specify which drugs those are. EMEA notes that "at present the GMP/GDP Inspectors Working Group agrees that the guide should indeed identify those products in which the use of dedicated facilities is mandatory. It is acknowledged that the drafting group needs input from toxicological and pharmacological experts in order to develop this part of the guidance so that it is based on well grounded scientific principles and this expertise has now been made available." EMEA says that its Safety Working Party will be developing the guidance and that a consultation draft will be submitted to the European Commission at yearend
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.